Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telmisartan + amlodipine + rosuvastatin is a fixed-dose combination therapy comprising three active pharmaceutical ingredients, each with distinct mechanisms of action targeting cardiovascular risk factors. Telmisartan is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the vasoconstrictive effects of angiotensin II, leading to vasodilation. Amlodipine is a calcium channel blocker (CCB) that inhibits calcium influx into vascular smooth muscle and cardiac muscle, resulting in relaxation of blood vessels and further reduction in blood pressure. Rosuvastatin is a statin that selectively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing low-density lipoprotein cholesterol (LDL-C) levels and increasing hepatic LDL receptor expression for enhanced clearance of LDL from plasma. This triple combination targets both hypertension and dyslipidemia simultaneously, improving patient compliance by reducing pill burden and providing comprehensive cardiovascular risk reduction[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on telmisartan + amlodipine + rosuvastatin.